Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …

Tumors contain hostile inflammatory signals generated by aberrant proliferation, necrosis,
and hypoxia. These signals are sensed and acted upon acutely by the Toll-like receptors (…

Glioblastoma (GBM) remains uniformly lethal, and despite a large accumulation of immune
cells in the microenvironment, there is limited antitumor immune response. To overcome …

Sexual dimorphism at the level of MDSC subset prevalence, localization, and gene-expression
profile constitutes a therapeutic opportunity. Our results indicate that chemotherapy can …

Background Cancer immunotherapy is associated with several immune-related adverse
events, but the relationship between immunotherapy and venous thromboembolism has not …

The application of tumor immunotherapy to glioblastoma (GBM) is limited by an unprecedented
degree of immune suppression due to factors that include high numbers of immune …

BACKGROUND Myeloid-derived suppressor cells (MDSCs) are elevated in the circulation
of patients with glioblastoma (GBM), present in tumor tissue, and associated with poor …

Tumors adapt their phenotypes during growth and in response to therapies through dynamic
changes in cellular processes. Connexin proteins enable such dynamic changes during …

Cancer stem cells (CSC) drive tumor growth in many cancers including GBM. We identified
a novel sheddase, ADAMDEC1, which initiates an FGF autocrine loop to promote stemness …

Purpose: Glioblastoma (GBM) immunotherapy clinical trials are generally initiated after
standard-of-care treatment—including surgical resection, perioperative high-dose steroid therapy…